Skip to Main Content

Hello, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, calls, and what-not has, of course, returned. You knew this would happen, yes? There is only one thing we can do under such circumstances and that is to fire up the coffee kettle to brew some cups of stimulation. Our choice this morning is almond toffee. Sounds tempting, yes? Well, either way, here are some tidbits to keep you focused. Hope your day goes well and do keep in touch …

Novartis (NVS) is exploring working with the global reinsurance industry to help health systems bear the cost of a new generation of personalized therapies as the industry comes under pressure to devise funding models for ultra-expensive medicines, The Financial Times reports. The drug maker is “brainstorming” alternative financing possibilities for drugs that offer the prospect of curing patients of once-fatal diseases, potentially saving substantial healthcare costs down the line — but requiring enormous upfront outlays.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!